DE69929683D1 - Antisense modulierung von lfa-3 - Google Patents

Antisense modulierung von lfa-3

Info

Publication number
DE69929683D1
DE69929683D1 DE69929683T DE69929683T DE69929683D1 DE 69929683 D1 DE69929683 D1 DE 69929683D1 DE 69929683 T DE69929683 T DE 69929683T DE 69929683 T DE69929683 T DE 69929683T DE 69929683 D1 DE69929683 D1 DE 69929683D1
Authority
DE
Germany
Prior art keywords
lfa
antisense modulation
treatment
modulation
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69929683T
Other languages
English (en)
Inventor
Frank Bennett
P Condon
Cheng Flournoy
S Pober
Weillie Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Ionis Pharmaceuticals Inc
Original Assignee
Yale University
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University, Isis Pharmaceuticals Inc filed Critical Yale University
Application granted granted Critical
Publication of DE69929683D1 publication Critical patent/DE69929683D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
DE69929683T 1998-03-20 1999-03-17 Antisense modulierung von lfa-3 Expired - Lifetime DE69929683D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/045,106 US6001651A (en) 1998-03-20 1998-03-20 Antisense modulation of LFA-3
PCT/US1999/005837 WO1999047707A1 (en) 1998-03-20 1999-03-17 Antisense modulation of lfa-3

Publications (1)

Publication Number Publication Date
DE69929683D1 true DE69929683D1 (de) 2006-04-13

Family

ID=21936028

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69929683T Expired - Lifetime DE69929683D1 (de) 1998-03-20 1999-03-17 Antisense modulierung von lfa-3

Country Status (7)

Country Link
US (1) US6001651A (de)
EP (1) EP1064402B1 (de)
JP (1) JP3590585B2 (de)
AT (1) ATE317021T1 (de)
AU (1) AU3189199A (de)
DE (1) DE69929683D1 (de)
WO (1) WO1999047707A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503754B1 (en) * 2000-09-07 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of BH3 interacting domain death agonist expression
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US20040006036A1 (en) * 2000-04-12 2004-01-08 Gmr, A Delaware Corporation Silencing transcription by methylation
SK287689B6 (sk) 2000-06-08 2011-06-06 Intercell Ag Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
US7105657B2 (en) * 2002-11-08 2006-09-12 Board Of Regents Of The University Of Nebraska Compositions and methods for inhibiting pancreatic cancer metastasis
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
DE4008354A1 (de) * 1990-03-15 1991-09-19 Basf Ag Neues protein, seine herstellung und verwendung
WO1992004463A1 (de) * 1990-09-04 1992-03-19 Basf Aktiengesellschaft Cd58 spezifischer monoklonaler antikörper und dessen verwendung
US5547853A (en) * 1991-03-12 1996-08-20 Biogen, Inc. CD2-binding domain of lymphocyte function associated antigen 3
EP0503646A1 (de) * 1991-03-12 1992-09-16 Biogen, Inc. Monoklonale Antikörper gegen Lymphozytenfunktionassoziertes Antigen-3
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
ATE210454T1 (de) * 1991-10-07 2001-12-15 Biogen Inc Verfahren zur verbesserung der toleranz für allotransplantaten und xenotransplantaten durch verabreichung eines lfa-3- oder cd2- bindungsproteins
EP0607332B1 (de) * 1991-10-07 1997-12-17 Biogen, Inc. Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
DK0671933T3 (da) * 1992-08-20 1998-09-23 Schering Corp Hidtil ukendte anvendelser af IL-10
SE9302738L (sv) * 1993-08-25 1995-02-26 Cito Trading Co Anordning för kraftöverföring mellan räl för spårbundet fordon och fundament
JPH10507906A (ja) * 1994-08-19 1998-08-04 ザ ジェネラル ホスピタル コーポレイション 遺伝子工学処理したブタ細胞
EP0867449A4 (de) * 1995-04-19 2000-08-09 Kanegafuchi Chemical Ind Zellädhasionsprotein, dier enthaltende immunsuppressive mittel, sowie immunsuppressiva, die zellen enthalten, welche damit induziert wurden
US7663394B2 (en) * 2006-01-25 2010-02-16 Nec Corporation Start signal detector circuit

Also Published As

Publication number Publication date
AU3189199A (en) 1999-10-11
US6001651A (en) 1999-12-14
EP1064402A4 (de) 2003-06-11
JP3590585B2 (ja) 2004-11-17
EP1064402A1 (de) 2001-01-03
EP1064402B1 (de) 2006-02-01
WO1999047707A1 (en) 1999-09-23
ATE317021T1 (de) 2006-02-15
JP2002506658A (ja) 2002-03-05

Similar Documents

Publication Publication Date Title
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP1064403A4 (de) Antisense modulation von pecam-1
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DK0817851T3 (da) DNA, der koder for humant papillomvirus type 18
ATE317021T1 (de) Antisense modulierung von lfa-3
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
AU4263696A (en) Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof
MX9806041A (es) Proteina purificada sr-p70.
SE9602822D0 (sv) New receptor
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69736180D1 (de) Behandlung von manischen erkrankungen
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE59809344D1 (de) Disubstituierte biphenyloxazoline
DE69802329D1 (de) Verfahren zur Herstellung von 3,4 disubstituirten Dinitroanilinen
IT8721945A0 (it) Procedimento per la profumazione di libri, dispositivo per l'attuazione di detto procedimento
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.

Legal Events

Date Code Title Description
8332 No legal effect for de